
Roche Holding Ltd. company operates two segments, pharmaceuticals and diagnostics, and sells its products in more than 150 countries. Roche's prescription drugs include cancer therapies MabThera/Rituxan and Herceptin, anemia treatment NeoRecormon/Epogin, hepatitis drug Pegasys, transplant drug CellCept, obesity treatment Xenical, and Tamiflu, which is used to prevent and treat influenza, including avian strains. The company markets many of its bestsellers through subsidiary Genentech and affiliate Chugai Pharmaceutical. Roche's diagnostics arm offers advanced DNA tests, diabetes monitoring supplies, and point-of-care diagnostics used in a variety of health care settings.

NeoPharm, Inc. was founded in 1990 and is headquartered in Lake Bluff, Illinois. NeoPharm, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases primarily in the United States. Its products include LEP-ETU, which is in Phase II trial for the treatment of breast and ovarian cancer; LE-DT that is in Phase I trial for the treatment of various forms of cancer; and LE-rafAON, which completed preclinical studies to treat pancreatic cancer. The company has a co-operative research and development agreement with the National Institute of Neurological Diseases and Stroke for research on a therapeutic agent for untreatable brain diseases in humans. NeoPharm would provide its proprietary drug, Cintredekin Besudotox (IL13-PE38QQR), and technical resources to study its effects in various brain cancers in humans. Its IL13-PE38QQR also completed preclinical studies for the treatment of idiopathic pulmonary fibrosis and asthma. The company was formerly known as OncoMed, Inc. and changed its name to NeoPharm, Inc. in March 1995.

Guerbet Group is one of Europe's leading makers of contrast agents used in medical imaging. Most of the company's products, such as Xenetix, Hexabrix, and Dotarem, are substances that are injected into the body to make internal organs visible during X-ray and magnetic resonance imaging (MRI) examinations. Subsidiary Simafex manufactures specialty chemicals for use in pharmaceuticals. Guerbet has operations in some 15 countries and is targeting growth in the US. Marcel Guerbet, grandfather of chairman Michel Guerbet, developed the first iodinated contrast agent around the turn of the century; his descendants control the company.

Osiris Therapeutics, Inc. company was founded in 1992 and is headquartered in Columbia, Maryland. Osiris Therapeutics, Inc., a stem cell therapeutic company, develops products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas in the United States. The company's principal product includes Prochymal, which is in phase III clinical trials for the treatment of steroid refractory Graft versus Host Disease (GvHD), acute GvHD, Crohn's disease, and acute radiation syndrome; and in phase II clinical trials for the treatment of Type I diabetes mellitus, acute myocardial infarction, and chronic obstructive pulmonary disease. Its product also consists of Chondrogen, a Phase II clinical trial product for the treatment of osteoarthritis and the reduction of pain in the knee. Osiris Therapeutics has collaboration agreements with Genzyme Corporation for the development and commercialization of Prochymal and Chondrogen; Juvenile Diabetes Research Foundation for the development of Prochymal as a treatment for the preservation of insulin production in patients with newly diagnosed type 1 diabetes; and JCR Pharmaceuticals Co., Ltd. for distributing Prochymal for the treatment of GvHD in Japan.

Infinity Pharmaceuticals, Inc. engages in the discovery and development of medicines for the treatment of cancer and related conditions. It is conducting an international Phase III registration study of its lead product candidate, retaspimycin hydrochloride (IPI-504), an intravenously-administered small molecule inhibitor of heat shock protein 90 (Hsp90), in patients with refractory gastrointestinal stromal tumors; and a Phase I/II clinical trial in patients with advanced non-small cell lung cancer. The company's developing products include IPI-504 in combination with Taxotere in Phase Ib clinical trial for patients with solid tumors; IPI-493, an orally-delivered inhibitor of Hsp90 for patients with advanced solid tumors in Phase I clinical trial; and IPI-926, a hedgehog pathway inhibitor for patients with advanced and/or metastatic solid tumors in Phase I clinical trial. Further, the company has a discovery program focusing on fatty acid amide hydrolase, an enzyme that degrades anandamide and is targeted for neuropathic pain; and developing compounds that target Bcl-2, or Bcl-2 and Bcl-xL anti-apoptotic proteins. Infinity Pharmaceuticals has strategic alliance agreements with Mundipharma International Corporation Limited and Purdue Pharmaceutical Products L.P. to develop and commercialize pharmaceutical products; and a product development and commercialization agreement with MedImmune, Inc. to develop and commercialize cancer drugs targeting Hsp90 and the hedgehog pathway.

LGC (Holdings) Limited company provides chemical, DNA and other scientific analysis through four operating divisions: LGC forensics, life and food sciences, research and technology, and LGC standards. Its customers are involved in such areas as drug development, health care services, chemicals and petrochemicals, law enforcement, and environmental quality and maintenance. The company's LGC Prochem unit sells enzymes, proteins, reagents, and other laboratory supplies. Investment firm 3i Group owns about 30% of LGC, as does its employees.

TapImmune Inc. is a biotechnology company specializing in the development of innovative therapeutics and vaccines in the areas of oncology and infectious disease. The company’s lead product, the TAP vaccine performs a key step in moving characteristic markers called antigens to the surfaces of cells. Without TAP, there are no cancer markers, so the immune system fails to spot the rogue cells and the cancerous cells can grow undetected. The Company’s vaccine has shown effective restoration of TAP which restores and augments the marker (antigen) presentation and subsequent recognition and killing of cancer cells by the immune system. The TAP molecule also works as an adjuvant or ‘accelerant’ to enhance targeted vaccines against infectious diseases. Including TAP in the studied Smallpox Vaccine showed potency was increased by 100-1000 times. The company is currently developing AdhTAP for the commencement of toxicology studies leading to the initiation of Phase I clinical trials. The global vaccine market is expected to grow from $13 billion in 2007 to $21 billion in 2010.

CardioVascular BioTherapeutics, Inc. (Cardio) is a development-stage biopharmaceutical company focused on developing drugs to stimulate the growth of new blood vessels for the treatment of cardiovascular diseases. The active pharmaceutical ingredient (API) in the Company’s drug candidates is acidic human fibroblast growth factor-1, FGF-1141 (formerly called Cardio Vascu-Grow) and it facilitates the growth of new blood vessels in the heart tissues and organs with an impaired vascular system. This process is referred to as angiogenesis in the scientific community. The Company’s research and development is focused on developing new drug candidates, in which FGF-1141 is the API for the treatment of cardiovascular diseases, where the growth of new blood vessels can improve the outcome for patients. The Company conducts research to identify and evaluate medical indications that may benefit from its drug candidates.

GlaxoSmithKline Research & Development is the actual pipeline filled with products in various stages of completion for pharmaceutical giant GlaxoSmithKline. With multiple locations in the US, across Europe, and Japan, the company has treatments in the works for ailments such as infectious diseases, neuroscientific requirements, cardiovascular ailments, oncology, and respiratory needs. It has approximately 150 pharmaceutical products in clinical trial stages. The organization's facilities are grouped into Molecular Discovery Research (preclinical), Centres of Excellence for Drug Discovery (early stage clinical), and Medicine Development Centres (late-stage clinical).

Cortex Pharmaceuticals develops drugs to treat neurodegenerative and psychiatric disorders. Its research focuses on the AMPA receptor, which facilitates communication between nerve cells; the firm's Ampakine compounds may enhance this receptor's activity. Its lead drug candidate is CX717, which it is developing for a number of indications including respiratory depression (a potentially fatal side effect of some anesthetics and post-surgical painkillers), Alzheimer's disease, attention deficit hyperactivity disorder (ADHD), and daytime sleepiness. The firm believes Ampakine drugs may also be helpful in treating a variety of other brain-related disorders, including depression, autism, and Huntington's disease.
Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.







.webp)
.webp)
.webp)
.webp)
.webp)





